Company Description
Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops therapeutics for cancer patients.
Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.
The company develops KROS 101, an orally available glucocorticoid-induced tumor necrosis factor receptor (GITR) ligand small-molecule antagonist to deplete regulatory T cells (Tregs) and activate effector T cells to augment the antitumor immune response for the treatment of patients with cancer, and a systemic immune modulator to address immunosuppressive activity of solid cancers; KROS 102, a GITR antagonist to increase the inhibitory regulatory Tregs functions; KROS 201 that activates the T cells using dendritic cells for the treatment of patients with glioblastoma; KROS 301, a tumor-targeting small molecule and checkpoint inhibitor with mechanisms of action resulting from blocking intranuclear localization of RelA, a key component of the NF-KB pathway, as well as targets tumor cells in RelA/p65 biomarker positive solid tumors; and KROS 401, a tumor microenvironment immune modulator and cyclic peptide inhibitor of IL-4 and IL-13 reversing tumor associated macrophage inhibition, and blocks the IL4/IL13 cytokine immune receptors for triple negative breast cancer.
It also develops ENV 105, an antibody therapeutic for the prostate cancer patients resistant to androgen-targeted therapy, which is in Phase 2 clinical trial; and ENV 205, an antibody fragment that targets mitochondrial DNA.
The company was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016.
Kairos Pharma, Ltd. was incorporated in 2013 and is based in Los Angeles, California.
| Country | United States |
| Founded | 2013 |
| IPO Date | Sep 16, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | John Yu |
Contact Details
Address: 2355 Westwood Boulevard, Suite 139 Los Angeles, California 90064 United States | |
| Phone | 310-948-2356 |
| Website | kairospharma.com |
Stock Details
| Ticker Symbol | KAPA |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.00 |
| CIK Code | 0001962011 |
| ISIN Number | US48301N1046 |
| Employer ID | 46-2993314 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. John S. Yu M.D., Ph.D. | Chief Executive Officer, Chairman and Secretary |
| Douglas W. Samuelson CPA | Chief Financial Officer |
| Dr. Neil A. Bhowmick Ph.D. | Chief Scientific Officer |
| Dr. Ramachandran Murali Ph.D. | Vice President of Research and Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 16, 2025 | DEFR14A | Filing |
| May 15, 2025 | SCHEDULE 13G | Filing |
| May 14, 2025 | 10-Q | Quarterly Report |
| May 6, 2025 | PRER14A | Filing |
| May 1, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 29, 2025 | 10-K/A | [Amend] Annual report |
| Apr 28, 2025 | 8-K | Current Report |
| Apr 25, 2025 | 424B3 | Prospectus |
| Apr 24, 2025 | EFFECT | Notice of Effectiveness |
| Apr 24, 2025 | 8-K | Current Report |